

Sanofi  
Form 6-K  
October 30, 2013

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**  
**PURSUANT TO RULE 13a-16 OR 15d-16**  
**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

---

**For the month of October 2013**

**Commission File Number: 001-31368**

**SANOFI**

(Translation of registrant's name into English)

**54, rue La Boétie, 75008 Paris, FRANCE**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Edgar Filing: Sanofi - Form 6-K

Form 20-F

Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes

No

If  Yes marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

---

## Edgar Filing: Sanofi - Form 6-K

In October 2013, Sanofi issued the statements attached hereto as Exhibits 99.1 to 99.5 which are incorporated herein by reference.

### Exhibit List

<b>Exhibit No.</b>	<b>Description</b>
Exhibit 99.1	Press release dated October 30, 2013: Third Quarter 2013 Results
Exhibit 99.2	Press release dated October 29, 2013: Sanofi Launches Action 2013 , a Worldwide Employee Stock Purchase Plan
Exhibit 99.3	Press release dated October 16, 2013: Sanofi and Regeneron Report Positive Top-line Results with Alirocumab from First Phase 3 Study of a PCSK9 Inhibitor for LDL Cholesterol Reduction
Exhibit 99.4	Press release dated October 11, 2013: FDA Approves Sanofi s Nasacort® Allergy 24HR for Over-the-Counter Use
Exhibit 99.5	Genzyme Product Sales Statement, for the Product Sales Measuring Period ended September 30, 2013

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: October 30, 2013

SANOFI

By */S/ John Felitti*  
Name: John Felitti  
Title: Associate Vice President,  
Corporate Law, Financial & Securities Law

**Exhibit Index**

<b>Exhibit No.</b>	<b>Description</b>
Exhibit 99.1	Press release dated October 30, 2013: Third Quarter 2013 Results
Exhibit 99.2	Press release dated October 29, 2013: Sanofi Launches Action 2013 , a Worldwide Employee Stock Purchase Plan
Exhibit 99.3	Press release dated October 16, 2013: Sanofi and Regeneron Report Positive Top-line Results with Alirocumab from First Phase 3 Study of a PCSK9 Inhibitor for LDL Cholesterol Reduction
Exhibit 99.4	Press release dated October 11, 2013: FDA Approves Sanofi s Nasacort® Allergy 24HR for Over-the-Counter Use
Exhibit 99.5	Genzyme Product Sales Statement, for the Product Sales Measuring Period ended September 30, 2013